HONG KONG – Brii Biosciences has entered into two significant partnerships to expand its pipeline. The first is a license and collaboration agreement with VBI Vaccines Ltd. and Vir Biotechnology Inc. focused on hepatitis B virus (HBV) infection. Brii Bio licensed greater China rights, which includes the Chinese mainland, Hong Kong, Macau and Taiwan, for a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in a deal that could be worth up to $129 million plus royalties.
HONG KONG – In just seven months, Singapore-based biotech company Tychan Pte Ltd. has moved its monoclonal antibody, TY-014, from initiation and into clinical development.
HONG KONG – Brii Biosciences has entered into two significant partnerships to expand its pipeline. The first is a license and collaboration agreement with VBI Vaccines Ltd. and Vir Biotechnology Inc. focused on hepatitis B virus (HBV) infection. Brii Bio licensed greater China rights, which includes the Chinese mainland, Hong Kong, Macau and Taiwan, for a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in a deal that could be worth up to $129 million plus royalties. The second is a China-based exclusive research agreement with Wuxi Biologics Co. Ltd. and Tsinghua University Institute for Immunology to discover and develop bispecific antibodies to treat infectious diseases and other immunologic disorders.
HONG KONG – In just seven months, Singapore-based biotech company Tychan Pte Ltd. has moved its monoclonal antibody, TY-014, from initiation and into clinical development.
